Highest-materiality recent filing
Shareholders approve increase in stock option plan shares by 900,000 at 2026 annual meeting
All 7 director nominees elected; broker non-votes of 614,643.
ProMIS Neurosciences Q1 net loss $8.2M; PRECISE-AD interim analysis expected early Q3 2026
Net loss of $8.2M for Q1 2026, vs $7.3M in Q1 2025; cash & equivalents $63.8M as of March 31.
Net loss of $39.7M in FY2025; R&D expense soared to $33.4M from $10.6M a year ago, driven by PRECISE-AD trial.
ProMIS Neurosciences raises up to $175M in PIPE; extends cash runway into 2028
Upfront gross proceeds ~$75M from ~6.8M common shares and 100K pre-funded warrants; up to ~$100M more from warrant exercise.
ProMIS Neurosciences regains Nasdaq minimum bid price compliance
Nasdaq confirmed compliance on Dec 12, 2025; matter closed.
ProMIS Neurosciences Announces 1-for-25 Reverse Stock Split Effective November 28, 2025
Reverse stock split at ratio 1:25 approved by board on Nov 17, 2025, effective Nov 28, 2025.
Shareholders approve reverse stock split authorization for ProMIS Neurosciences
Special meeting on Nov 17, 2025; 24.3M of 53.8M shares voted (45% quorum).
ProMIS Neurosciences reports Q3 2025 results; Phase 1b AD trial over 85% enrolled
Cash $15.4M at Sep 30, 2025, up from $13.3M at Dec 31, 2024; raised ~$21.6M in July 2025.
ProMIS Neurosciences appoints Slanix Paul Alex, Pharm.D., to board of directors
Dr. Alex is President and Portfolio Manager for Ally Bridge Group, a major shareholder; joined board effective Oct 22, 2025.
ProMIS Neurosciences amends CSO Neil Cashman's employment agreement with new salary, option grant
Annual base salary increased to $500,000 CAD; discretionary bonus target of 35% of base salary.
ProMIS Neurosciences advances PMN310 to final dose cohort in Alzheimer's Phase 1b trial
DSMB unanimously recommends proceeding to third and final dose escalation cohort (20 mg/kg) after safety review.
ProMIS Neurosciences enters up to $18M at-the-market equity offering with H.C. Wainwright
ATM agreement filed Aug 19, 2025; allows sale of up to $17,988,524 in common shares.
ProMIS Neurosciences Q2 net loss $10.1M; PRECISE-AD enrollment >50%, no ARIA; raised $21.6M in July
Net loss $10.1M for Q2 2025 vs $2.6M a year ago; R&D spend $8.7M on PRECISE-AD trial.
ProMIS Neurosciences raises $3M from PIPE; total proceeds of ~$12M including warrant exercises
Raised ~$3M gross via PIPE sale of warrants at $0.1875/share with exercise price $1.25; closing July 29, 2025.
FDA grants Fast Track for PMN310; ATM program terminated after minimal sales
FDA granted Fast Track Designation to PMN310 for Alzheimer's disease.
ProMIS raises $9.2M via $0.8M registered direct and $2.4M PIPE plus $6.8M warrant exercises
Registered direct offering of pre-funded warrants for 984,736 shares at $0.8124 per share, gross ~$0.8M.
Nasdaq granted a second 180-day compliance period until December 29, 2025, to regain $1.00 minimum bid price.
ProMIS Neurosciences shareholders approve 2025 stock plan and reelect directors
Shareholders approved 2025 Stock Option and Incentive Plan: 8,124,425 for, 828,874 against, 1,143,067 abstain.
ProMIS Q1 net loss $7.3M; completes first cohort enrollment in PRECISE-AD trial
Net loss $7.3M vs $3.6M YoY; R&D expense $5.5M on PMN310 Phase 1b trial costs.
ProMIS Neurosciences reports FY 2024 net income $2.8M; Phase 1b PRECISE-AD enrolling
Cash $13.3M at Dec 31, 2024; PIPE financing provided $30.3M upfront with potential $92.4M from warrants.
First patients dosed in Phase 1b PRECISE-AD trial evaluating PMN310, a humanized mAb targeting toxic Aβ oligomers.
ProMIS Neurosciences separates with COO Gavin Malenfant; position eliminated.
Gavin T. Malenfant separated as COO effective February 14, 2025.
ProMIS Neurosciences releases updated corporate presentation; no material new data disclosed
Presentation dated January 27, 2025, posted to company website.
ProMIS initiates Phase 1b PRECISE-AD trial of PMN310 in Alzheimer's disease
Phase 1b PRECISE-AD trial initiated; evaluating PMN310 in 100 patients with early Alzheimer's over 12 months.
Received Nasdaq notice on Jan 3, 2025 for failing $1 minimum bid price rule for 30 consecutive trading days.
ProMIS Q3 net income $9.3M, cash $21.5M; Phase 1a positive; PIPE up to $122.7M
Net income of $9.3M for Q3 2024 vs net loss of $2.4M YoY, driven by $17.0M gain on warrant liabilities.
ProMIS Neurosciences shareholders approve stock issuance for warrants at special meeting
Proposal 1 (stock issuance for warrants) passed with 8,948,590 votes for, 121,116 against, 23,726 abstain.
Neil Warma appointed President and CEO of ProMIS Neurosciences, effective August 1, 2024
Base salary of $500,000 with annual discretionary bonus target of 50% of base salary.
ProMIS Neurosciences Q2 2024: Positive Phase 1a data for PMN310; secures up to $122.7M PIPE
Phase 1a of PMN310 in Alzheimer's showed no SAEs; CSF levels >100x oligomer concentration, half-life ~25 days supporting monthly dosing.
ProMIS Neurosciences regains compliance with Nasdaq market value listing requirement
Received Nasdaq notice on July 22 confirming compliance with $35M minimum market value of listed securities.
ProMIS reports positive Phase 1a data for PMN310 in Alzheimer's
PMN310 well-tolerated across four SAD cohorts (2.5-20 mg/kg); no treatment-emergent SAEs.
ProMIS Neurosciences raises $30.3M in PIPE financing with warrants for up to $92.4M more
Gross proceeds of $30.3M from sale of 9,757,669 common units at $2.15/unit and 4,371,027 pre-funded units at $2.14/unit.
ProMIS Neurosciences receives Nasdaq notice for MVLS non-compliance
Received notice from Nasdaq on July 2, 2024, for failing to maintain minimum Market Value of Listed Securities of $35M over 30 consecutive business days.
ProMIS Neurosciences annual meeting approves all four proposals including director elections
All seven director nominees elected, including Eugene Williams (4.15M for) and Neil Cashman (4.61M for); broker non-votes 3.23M.
ProMIS Neurosciences Q1 net loss $3.6M; cash $2.5M; Phase 1a data on track for mid-2024
Cash and equivalents $2.5M at March 31, 2024, down from $12.6M at Dec 31, 2023.
ProMIS publishes study showing PMN310's superior oligomer selectivity vs other Aβ antibodies
PMN310 displayed greatest selectivity for toxic soluble Aβ oligomers among tested antibodies.
Cash and cash equivalents $12.6M at Dec 31, 2023, up from $5.9M; Q3 2023 PIPE raised $20.4M gross.
Promis Neurosciences enters $25M ATM offering agreement with BTIG
At-the-market offering up to $25M of common shares via BTIG as sales agent.
ProMIS Neurosciences appoints Neil Warma as interim CEO after Gail Farfel departure
CEO Gail Farfel separated as President/CEO and Board member effective Dec 30, 2023; will receive severance per agreement.
ProMIS Neurosciences exchanges Series 1 Preferred for Series 2 at 60:1; no Series 1 outstanding
70,000,000 Series 1 Preferred exchanged for 1,166,667 Series 2 Preferred (60:1 ratio).
Promis Neurosciences doses first subject in Phase 1a trial of PMN310 for Alzheimer's
First-in-human Phase 1a study of PMN310, a monoclonal antibody selective for toxic Aβ oligomers, is underway.
ProMIS Q3 net loss $2.4M, cash $16.9M; starts Phase 1a PMN310 Alzheimer's trial
Net loss $2.4M in Q3 2023 vs $6.0M in Q3 2022; R&D expenses dropped to $1.1M from $4.6M.
ProMIS Neurosciences raises $20.4M in PIPE financing to fund clinical development
Gross proceeds of ~$20.4M from sale of common share units at $1.88/unit and pre-funded units at $1.87/unit.
ProMIS Q2 net loss $2.3M; cash drops to $1.2M; PMN310 IND cleared
Net loss $2.3M vs $2.7M YoY; R&D expense fell to $1.0M from $3.2M.
ProMIS Neurosciences continues from CBCA into Ontario under OBCA
Continuance effective July 13, 2023; approved by shareholders on June 29, 2023.
ProMIS Neurosciences to voluntarily delist from TSX, consolidate trading to Nasdaq
Voluntary delisting from TSX effective as of close of trading on July 21, 2023.
ProMIS Neurosciences shareholders elect all eight directors, ratify auditor, approve continuance
All eight director nominees elected: highest 3.47M for Cashman; lowest 3.05M for Wyman; broker non-votes 914k.
ProMIS reports Q1 2023 results, FDA clears IND for Alzheimer's candidate PMN310
FDA cleared IND for lead therapeutic candidate PMN310 for Alzheimer's disease; phase 1 enabling activities underway.
ProMIS Neurosciences receives FDA IND clearance for Alzheimer's antibody PMN310
FDA cleared IND for PMN310, a monoclonal antibody targeting toxic amyloid-beta oligomers in Alzheimer's disease.
ProMIS Neurosciences submits IND to FDA for Alzheimer's antibody PMN310
IND filed for PMN310, a monoclonal antibody targeting toxic amyloid-beta oligomers in Alzheimer's disease.
On February 14, 2025, ProMIS Neurosciences Inc. (the “Company”) separated with Gavin T. Malenfant as Chief Operating Officer of the Company, effective as of February 14, 2025
On October 8, 2024, ProMIS Neurosciences Inc. (the “Company”) appointed Neil Warma as the President and Chief Executive Officer (“CEO”) of the Company, effective August 1, 2024.
Effective December 30, 2023, the Board appointed Neil Warma as President and interim Chief Executive Officer and principal executive officer of the Company (the “Appointment”).
it separated with Gail Farfel, Ph.D. as President and Chief Executive Officer and principal executive officer of the Company, and as a member of the Board of Directors of the Company (the “Board”), in each case, effective as of December 30, 2023
On March 29, 2023, Richard Gregory, a member of the Board of Directors (the “ Board ”) of ProMIS Neurosciences Inc. (the “ Company ”), notified the Company of his intent to not stand for re-election to the Board at the Company’s 2023 Annual Meeting of Stockholders (the “ Annual Meeting ”) and, as a result, his term as a director of the Company, or on any committee of the Board, will end upon the conclusion of the Annual Meeting.
Eugene Williams, the Company’s Chief Executive Officer and principal executive officer will step down from his officer position with the Company, effective immediately
the Board of Directors (the " Board ") of the Company approved the appointment of Gail Farfel, Ph.D. as the Company’s Chief Executive Officer, effective September 19, 2022.
Max materiality 0.80 · Median 0.65 · Most common event other_material